Our study focuses on evaluating the combined efficacy of EZH2 inhibition and the immune checkpoint inhibitor anti-PD-1 specifically in cytotoxic T lymphocytes co-cultured Burkitt’s lymphoma. Here, PDCD1 is linked to Burkitt lymphoma.